Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Epidemiology, disease progression, and economic burden of colorectal cancer.

Benson AB 3rd.

J Manag Care Pharm. 2007 Aug;13(6 Suppl C):S5-18. Review.

PMID:
17713990
2.

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.

Tappenden P, Jones R, Paisley S, Carroll C.

Health Technol Assess. 2007 Mar;11(12):1-128, iii-iv. Review.

3.

Advances in the management of colorectal cancer: from biology to treatment.

Ahmed S, Johnson K, Ahmed O, Iqbal N.

Int J Colorectal Dis. 2014 Sep;29(9):1031-42. doi: 10.1007/s00384-014-1928-5. Epub 2014 Jun 24. Review.

PMID:
24953060
4.

Chemoprevention of colorectal cancer: systematic review and economic evaluation.

Cooper K, Squires H, Carroll C, Papaioannou D, Booth A, Logan RF, Maguire C, Hind D, Tappenden P.

Health Technol Assess. 2010 Jun;14(32):1-206. doi: 10.3310/hta14320. Review.

5.

[Recent results of irinotecan therapy in colorectal cancer].

Láng I, Hitre E.

Magy Onkol. 2004;48(4):281-8. Epub 2005 Jan 17. Review. Hungarian.

6.

Metastatic colorectal cancer.

Kindler HL, Shulman KL.

Curr Treat Options Oncol. 2001 Dec;2(6):459-71. Review.

PMID:
12057092
7.
8.

Colorectal liver metastasis: towards the integration of conventional and molecularly targeted therapeutic approaches.

Lise M, Mocellin S, Pilati P, Nitti D.

Front Biosci. 2005 Sep 1;10:3042-57. Review.

PMID:
15970559
9.

The management of colorectal liver metastases: Expanding the role of hepatic resection in the age of multimodal therapy.

Chiappa A, Makuuchi M, Lygidakis NJ, Zbar AP, Chong G, Bertani E, Sitzler PJ, Biffi R, Pace U, Bianchi PP, Contino G, Misitano P, Orsi F, Travaini L, Trifirò G, Zampino MG, Fazio N, Goldhirsch A, Andreoni B.

Crit Rev Oncol Hematol. 2009 Oct;72(1):65-75. doi: 10.1016/j.critrevonc.2008.11.003. Epub 2009 Jan 14. Review.

PMID:
19147371
10.

Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.

García-Foncillas J, Díaz-Rubio E.

Clin Transl Oncol. 2010 Aug;12(8):533-42. doi: 10.1007/s12094-010-0551-3. Review.

PMID:
20709651
11.

Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.

Stein A, Glockzin G, Wienke A, Arnold D, Edelmann T, Hildebrandt B, Hollerbach S, Illerhaus G, Königsrainer A, Richter M, Schlitt HJ, Schmoll HJ.

BMC Cancer. 2012 Aug 16;12:356. doi: 10.1186/1471-2407-12-356. Review.

12.

Multidisciplinary approach of colorectal liver metastases.

Juez I, Rubio C, Figueras J.

Clin Transl Oncol. 2011 Oct;13(10):721-7. doi: 10.1007/s12094-011-0722-x. Review.

PMID:
21975333
13.

Management of colorectal cancer presenting with synchronous liver metastases.

Siriwardena AK, Mason JM, Mullamitha S, Hancock HC, Jegatheeswaran S.

Nat Rev Clin Oncol. 2014 Aug;11(8):446-59. doi: 10.1038/nrclinonc.2014.90. Epub 2014 Jun 3. Review.

PMID:
24889770
14.

Updated options for liver-limited metastatic colorectal cancer.

Alberts SR.

Clin Colorectal Cancer. 2008 Dec;7 Suppl 2:S58-62. doi: 10.3816/CCC.2008.s.009. Review.

PMID:
19064408
15.

Colorectal cancer.

Nicum S, Midgley R, Kerr DJ.

Acta Oncol. 2003;42(4):263-75. Review.

PMID:
12899497
16.

Treatment decisions after diagnosis of metastatic colorectal cancer.

Cartwright TH.

Clin Colorectal Cancer. 2012 Sep;11(3):155-66. doi: 10.1016/j.clcc.2011.11.001. Epub 2011 Dec 21. Review.

PMID:
22192364
17.

Update and review of the multidisciplinary management of stage IV colorectal cancer with liver metastases.

Abdel-Misih SR, Schmidt CR, Bloomston PM.

World J Surg Oncol. 2009 Sep 29;7:72. doi: 10.1186/1477-7819-7-72. Review.

18.

The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.

Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A.

Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. Review.

19.

Strategies to treat primary unresectable colorectal liver metastases.

Vibert E, Canedo L, Adam R.

Semin Oncol. 2005 Dec;32(6 Suppl 8):33-9. Review.

PMID:
16360011
20.

Screening, prevention and socioeconomic costs associated with the treatment of colorectal cancer.

Redaelli A, Cranor CW, Okano GJ, Reese PR.

Pharmacoeconomics. 2003;21(17):1213-38. Review.

PMID:
14986736
Items per page

Supplemental Content

Write to the Help Desk